LIZABETH MUNZ SACHS APRN
Prescription History 1083007686
Nurse Practitioner - Adult Health in Stamford, CT


Quality Rating: 79.07 out of 100 score

NPI Status: Active since March 06, 2015

Contact Information

190 W BROAD ST
STAMFORD, CT
ZIP 06902
Phone: (203) 348-2437

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for LIZABETH MUNZ SACHS APRN, an active Adult Health specialist practicing in Stamford, CT. Our medical registry currently tracks 25 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,504 documented patient claims. Among these therapy options, the most frequently utilized medication is Trelegy Ellipta, which accounts for 256 claims alone.


Advair Diskus

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 33
30-Day Fills 55.0
Days Supply 1,650
CT State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills32.5
Peer Average Days Supply969
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 57.1% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $26,664.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$808.02

State Avg Cost Per Claim

$658.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 206
30-Day Fills 302.0
Days Supply 8,560
CT State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills66.9
Peer Average Days Supply1,688
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 274.5% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,529.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$46.26

State Avg Cost Per Claim

$47.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 127
30-Day Fills 189.0
Days Supply 5,670
CT State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills61.1
Peer Average Days Supply1,800
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 188.6% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $93,408.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$735.50

State Avg Cost Per Claim

$638.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Arnuity Ellipta

Generic Formulation: Fluticasone FuroateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 44
30-Day Fills 66.0
Days Supply 1,980
CT State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills42.0
Peer Average Days Supply1,259
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 57.1% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,432.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$373.47

State Avg Cost Per Claim

$348.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Azelastine-Fluticasone

Generic Formulation: Azelastine/FluticasoneSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 14
30-Day Fills 18.0
Days Supply 540
CT State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills28.7
Peer Average Days Supply839
Conservative Utilization

This provider writes prescriptions for this formulation 30.0% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,742.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$195.86

State Avg Cost Per Claim

$212.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to relieve seasonal allergy symptoms of the nose such as stuffy/runny nose, itching, sneezing, and post-nasal drip. It contains 2 drugs. Azelastine is an antihistamine that works by blocking certain natural substances called histamines that are responsible for allergic symptoms. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) in the nasal passages.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 27
30-Day Fills 32.8
Days Supply 381
CT State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills33.5
Peer Average Days Supply283
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $228.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.46

State Avg Cost Per Claim

$10.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 167
30-Day Fills 231.0
Days Supply 6,930
CT State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills61.9
Peer Average Days Supply1,829
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 271.1% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $96,968.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$580.65

State Avg Cost Per Claim

$544.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Breztri Aerosphere

Generic Formulation: Budesonide/Glycopyr/FormoterolSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 21
30-Day Fills 35.0
Days Supply 1,050
CT State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills48.0
Peer Average Days Supply1,435
Conservative Utilization

This provider writes prescriptions for this formulation 41.7% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $23,564.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,122.13

State Avg Cost Per Claim

$835.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 3 medications: budesonide, glycopyrrolate, and formoterol. Budesonide works by reducing the irritation and swelling of the airways. Budesonide belongs to a class of drugs known as corticosteroids. Glycopyrrolate and formoterol work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This medication is not approved to treat asthma.

Clarithromycin

Generic Formulation: ClarithromycinSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
CT State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills15.6
Peer Average Days Supply195
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $672.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$56.02

State Avg Cost Per Claim

$39.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.

Therapeutic Applications

Clarithromycin is used to treat a wide variety of bacterial infections. This medication can also be used in combination with anti-ulcer medications to treat certain types of stomach ulcers. It may also be used to prevent certain bacterial infections. Clarithromycin is known as a macrolide antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Combivent Respimat

Generic Formulation: Ipratropium/Albuterol SulfateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
CT State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills23.9
Peer Average Days Supply693
Conservative Utilization

This provider writes prescriptions for this formulation 38.9% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,715.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$519.59

State Avg Cost Per Claim

$648.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to treat and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). This product contains 2 medications: ipratropium and albuterol (also known as salbutamol). Both drugs work by relaxing the muscles around the airways so that the airways open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Dupixent Pen

Generic Formulation: DupilumabSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 69
30-Day Fills 69.0
Days Supply 1,932
CT State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills26.8
Peer Average Days Supply738
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 176.0% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $258,890.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,752.04

State Avg Cost Per Claim

$3,859.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain skin conditions (eczema, prurigo nodularis) and a certain esophagus problem (eosinophilic esophagitis). It is also used along with other medications to help control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. In addition, dupilumab may be used to reduce symptoms caused by nasal polyps and the long-term swelling of the sinuses and nasal passage (chronic rhinosinusitis with nasal polyposis). Dupilumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking certain natural proteins in your body (interleukin-4 and interleukin-13) that may cause inflammation and swelling. This medication should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fasenra Pen

Generic Formulation: BenralizumabSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 34
30-Day Fills 57.6
Days Supply 1,708
CT State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills30.2
Peer Average Days Supply898
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 100.0% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $216,236.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,359.89

State Avg Cost Per Claim

$6,103.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Benralizumab is used along with other medications to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler as prescribed.

Fluticasone Propionate

Generic Formulation: Fluticasone PropionateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 132
30-Day Fills 293.1
Days Supply 8,763
CT State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills76.0
Peer Average Days Supply2,268
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 207.0% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,093.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.01

State Avg Cost Per Claim

$20.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone-Salmeterol

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 15
30-Day Fills 25.0
Days Supply 750
CT State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills25.8
Peer Average Days Supply773
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,771.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$251.41

State Avg Cost Per Claim

$277.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 26
30-Day Fills 56.0
Days Supply 1,680
CT State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills36.6
Peer Average Days Supply1,044
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $21,590.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$830.40

State Avg Cost Per Claim

$486.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 75
30-Day Fills 211.8
Days Supply 6,355
CT State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills121.1
Peer Average Days Supply3,601
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 41.5% more claims than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,860.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.81

State Avg Cost Per Claim

$19.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Prednisone

Generic Formulation: PrednisoneSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 45
30-Day Fills 51.0
Days Supply 639
CT State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills60.6
Peer Average Days Supply1,246
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $208.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.63

State Avg Cost Per Claim

$7.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Spiriva Respimat

Generic Formulation: Tiotropium BromideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 43
30-Day Fills 64.0
Days Supply 1,920
CT State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills48.7
Peer Average Days Supply1,458
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 34.4% more claims than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $35,469.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$824.88

State Avg Cost Per Claim

$760.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Stiolto Respimat

Generic Formulation: Tiotropium Br/Olodaterol HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 17
30-Day Fills 43.0
Days Supply 1,290
CT State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills39.8
Peer Average Days Supply1,187
Conservative Utilization

This provider writes prescriptions for this formulation 34.6% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $21,014.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,236.16

State Avg Cost Per Claim

$716.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: tiotropium and olodaterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Olodaterol belongs to the class of drugs known as long-acting inhaled beta-agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Tiotropium/olodaterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as olodaterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 42
30-Day Fills 78.0
Days Supply 2,340
CT State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills49.6
Peer Average Days Supply1,486
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $30,221.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$719.56

State Avg Cost Per Claim

$557.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Theophylline Er

Generic Formulation: Theophylline AnhydrousSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 13
30-Day Fills 23.0
Days Supply 680
CT State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills22.4
Peer Average Days Supply655
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $830.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$63.90

State Avg Cost Per Claim

$194.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination that contains THEOPHYLLINE and ethylenediamine. It is more soluble in water than theophylline but has similar pharmacologic actions. It's most common use is in bronchial asthma, but it has been investigated for several other applications.

Therapeutic Applications

Theophylline is used to treat lung diseases such as asthma and COPD (bronchitis, emphysema). It must be used regularly to prevent wheezing and shortness of breath. This medication belongs to a class of drugs known as xanthines. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. It also decreases the lungs' response to irritants. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 256
30-Day Fills 374.0
Days Supply 11,220
CT State Average Benchmarks
Peer Average Claims75.0
Peer Average 30-Day Fills104.7
Peer Average Days Supply3,118
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 241.3% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $256,348.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,001.36

State Avg Cost Per Claim

$900.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Ventolin Hfa

Generic Formulation: Albuterol SulfateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 32
30-Day Fills 42.6
Days Supply 1,219
CT State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills28.0
Peer Average Days Supply699
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 39.1% more claims than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,499.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$109.36

State Avg Cost Per Claim

$78.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Wixela Inhub

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 27
30-Day Fills 53.0
Days Supply 1,590
CT State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills36.9
Peer Average Days Supply1,107
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $12,205.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$452.07

State Avg Cost Per Claim

$371.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Xolair

Generic Formulation: OmalizumabSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 448
CT State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills31.4
Peer Average Days Supply877
Conservative Utilization

This provider writes prescriptions for this formulation 44.8% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $116,803.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$7,300.22

State Avg Cost Per Claim

$3,645.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA.

Therapeutic Applications

Omalizumab is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma that is due to year-round allergens. Controlling symptoms of asthma helps you maintain your normal activities and cuts down on time lost from work or school. Omalizumab may also be used to treat nasal polyps or to treat hives from an unknown cause (chronic idiopathic urticaria-CIU). This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, salbutamol) as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like LIZABETH MUNZ SACHS APRN provides transparency into local medical care patterns within Stamford, CT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Adult Health** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.